Application of controlled high dose rates in UV-B phototherapy for psoriasis

Schothorst, A.A.; Boer, Jurr; Suurmond, D.; Kenter, C. A. C.

doi:10.1111/j.1365-2133.1984.tb07316.x

Cited by 18 publications

(3 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For these reasons, protection factors will be higher than the AF we have calculated. Studies with UVB have typically found, after at least nine sessions, protection factors of 2-13 (Cripps, 1981;Schothorst et al, 1984;Taylor and Stern, 1991;Gonzalez et al, 1996;Sheehan et al, 1998Sheehan et al, , 2002de Winter et al, 2001). Differences in photoadaptation by body site have not, to our knowledge, been reported (Waterston et al, 2004).…”

Section: Discussionmentioning

confidence: 91%

Photoadaptation during Narrowband Ultraviolet-B Therapy Is Independent of Skin Type: A Study of 352 Patients

Palmer

Aquilina

Milligan

et al. 2006

Journal of Investigative Dermatology

View full text Add to dashboard Cite

Understanding how photoadaptation differs between individuals is important when considering susceptibility to the beneficial and harmful effects of sunlight exposure and when determining optimal phototherapy regimens. Most narrowband UVB (NB-UVB) regimens start with 70% of the minimal erythema dose (MED) with 20% increments at each treatment thereafter. We retrospectively studied 352 skin types I-IV psoriatic patients having twice weekly treatment with this regimen. Patients with high skin types tended to have high MEDs (P<0.001). By session 20 the proportion of patients who had developed erythema was approximately 60% regardless of MED. Among patients who developed erythema, the number of treatments before erythema occurred did not differ between skin types (P=0.33). We conclude that patients with high skin types photoadapt approximately equally per physical unit of UVR in comparison to those with low skin types, but they have greater photoadaptation in absolute terms because they are able to tolerate a higher initial dose of radiation. Differences in skin type or MED are not associated with clinically important differences in tendency to erythema during a standard 70/20% NB-UVB twice-weekly regimen. This regimen is suitable for all skin types I-IV patients regardless of skin type or MED.

show abstract

Section: Discussionmentioning

confidence: 91%

Photoadaptation during Narrowband Ultraviolet-B Therapy Is Independent of Skin Type: A Study of 352 Patients

Palmer

Aquilina

Milligan

et al. 2006

Journal of Investigative Dermatology

View full text Add to dashboard Cite

show abstract

“…Eight of the studies used solar-simulated UVR (SSR) (12)(13)(14)(15)(16)(19)(20)(21), while the remaining two studies exposed participants to a non-solar phototherapy source (17,18) (Table 1). For both studies (17,18) the UVR source was a lamp with a full width at half maximum (FWHM) waveband ranging from $ 305-335nm along with a UVAI spike between 360 and 370 nm (22).…”

Section: Resultsmentioning

confidence: 99%

Prevention of DNA damage in human skin by topical sunscreens

Olsen

Wilson

Green

et al. 2017

Photoderm Photoimm Photomed

View full text Add to dashboard Cite

show abstract

“…Several investigators have stated in the past that erythema induction is a prerequisite needed for UVB phototherapy to be effective. Fisher et al and others [27, 28, 29] have shown that the longer wavelengths of UVB over 310 nm have therapeutic effects and do not induce erythema and Koebner effects. This has led to the development of TL-01 narrow-band (311 nm) UVB phototherapy [12].…”

Section: Discussionmentioning

confidence: 99%

Low-Dose Narrow-Band UVB Phototherapy Combined with Topical Therapy Is Effective in Psoriasis and Does Not Inhibit Systemic T-Cell Activation

Rie

Out²,

Bos³

1998

Dermatology

View full text Add to dashboard Cite

Background: Psoriasis is a chronic T-cell-mediated inflammatory skin disease which can be treated with topical medication, phototherapy or systemic medication. A subgroup of psoriatic patients does not respond to monotherapy and needs combination therapy. We used low-dose narrow-band UVB phototherapy, combined with balneotherapy, short-contact anthralin, liquor carbonis detergens and calcipotriol for treatment of psoriatic patients in our day care centre. Objective: Our purpose was to study the efficacy, induction of erythema and effect on systemic T-cell activation of this combination therapy. Methods: Skin reflectance spectrophotometry was used to measure skin erythema. The Psoriasis Area and Severity Index (PASI) was used to evaluate psoriatic patients. Serum soluble IL-2 receptor (sIL2-R) levels were measured by an ELISA. Results: The possible erythematogenic effect of low-dose narrow-band UVB irradiation was studied (skin reflectance spectrophotometer) in a control group of psoriatic patients (n = 11). No induction of skin erythema was seen. Subsequently, this low-dose irradiation regimen was used in combination with topical medication in 26 psoriatic patients. A 90% decrease in the PASI was seen after a mean number of 35 treatment sessions. Seventeen patients (65%) remained in remission during the following 6 months. Serum sIL-2R levels were elevated in all patients (mean 913 U/ml) and did not change during treatment. Conclusion: Our data indicate that low-dose narrow-band UVB can be used successfully, in combination with topical treatment, in a day care setting to treat psoriatic patients. Since sIL-2R serum levels were not decreased, it can be speculated that this treatment does not induce systemic immunosuppression.

show abstract

Application of controlled high dose rates in UV-B phototherapy for psoriasis

Cited by 18 publications

References 10 publications

Photoadaptation during Narrowband Ultraviolet-B Therapy Is Independent of Skin Type: A Study of 352 Patients

Photoadaptation during Narrowband Ultraviolet-B Therapy Is Independent of Skin Type: A Study of 352 Patients

Prevention of DNA damage in human skin by topical sunscreens

Low-Dose Narrow-Band UVB Phototherapy Combined with Topical Therapy Is Effective in Psoriasis and Does Not Inhibit Systemic T-Cell Activation

Contact Info

Product

Resources

About